Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional)
Funding Opportunity RFA-CA-24-006 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity Announcement (NOFO), the National Cancer Institute (NCI) intends to expand the research scope and leverage the gains made through the NOFO entitled Investigation of the Transmission of KSHV (RFA-CA-18-013 and RFA-CA-20-046) to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-a...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 16, 2023 Category: Research Source Type: funding
Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network - Coordination and Data Sharing Center (CDSC) (UG3/UH3 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-23-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications from single institutions or consortia of institutions to establish a Coordination and Data Sharing Center (CDSC) in support of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers. Together, the CDSC and ReVAMPP Centers will form the ReVAMPP Network. The purpose of the CDSC is to support, coordinate, and manage ongoing and planned activities within the ReVAMPP Network. The CDSC is expected to establish and maintain a col...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 16, 2023 Category: Research Source Type: funding
Maintaining Immunity after Immunization (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-22-055 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to promote research to improve our understanding of how vaccines against infectious agents lead to durable protective immunity. This initiative will support studies that define components and mechanisms of the immune system that determine such durability. Applications must propose the use of human cells/tissues to decipher the human response elicited through vaccination. Animal studies also may be included to elucidate mechanistic pathways not easily accomplished with human samples. (...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 22, 2022 Category: Research Source Type: funding
Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-21-007 from the NIH Guide for Grants and Contracts. To support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 19, 2021 Category: Research Source Type: funding
Continued Impact of COVID-19 on Biomedical Research
It’s been over eight months since the COVID-19 pandemic crisis struck, changing every facet of life as we knew it. The U.S. biomedical research enterprise was not spared, as lockdowns and severe restrictions on activities took hold across the country. At the time, we offered our perspectives on efforts we could take to cushion the shock. Since that time, much has happened. COVID-19 research has blossomed with impressive results including FDA approval of a therapeutic agent (remdesivir, which was found to have value in a large-scale NIH-funded trial), development of several candidate vaccines that have already made to piv...
Source: NIH Extramural Nexus - November 4, 2020 Category: Research Authors: Mike Lauer Tags: blog Open Mike COVID 19 Source Type: funding
Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-20-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support novel strategies for the rational design of vaccines against hepatitis C virus (HCV), to assess the vaccines for their ability to induce protective immune responses, and to select candidates for preclinical development and clinical testing. To this end, it will be critical to advance knowledge of the structural basis for broad immunological protection, and to elucidate correlates of HCV protection by leveraging samples from existing human cohorts and vaccine studies. Thi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 24, 2020 Category: Research Source Type: funding
Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R21 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-247 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 11, 2019 Category: Research Source Type: funding
Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-248 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 11, 2019 Category: Research Source Type: funding
Immunity in the Elderly (R01) Clinical Trial Optional
Funding Opportunity RFA-AI-17-037 from the NIH Guide for Grants and Contracts. The goal of this reissued Funding Opportunity Announcement (FOA) is to expand understanding of age-related changes that occur in immune function during the aging process that influence responses to pathogens and/or vaccines, as well as oral and craniofacial health. Human studies are required, and inclusion of relevant animal studies is permitted for mechanistic understanding. This FOA solicits applications that will determine the mechanisms required for induction and maintenance of protective immunity in the elderly in response to infections ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 25, 2017 Category: Research Source Type: funding
Pan American Health Organization (PAHO) Building Capacity and Networks to Address Emerging Infectious Diseases in the Americas (CK-1301-04SUPP2017)
Funding Opportunity ID: 292838 Opportunity Number: CDC-RFA-CK13-1301 Opportunity Title: Pan American Health Organization (PAHO) Building Capacity and Networks to Address Emerging Infectious Diseases in the Americas (CK-1301-04SUPP2017)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCategory Explanation: CFDA Number(s): 93.099Eligible Applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification)Additional Information on Eligibility: Pan American Health Organizati...
Source: Grants.gov - March 29, 2017 Category: Research Tags: Health Source Type: funding
HIV/AIDS Vaccine Facility (C06)
Funding Opportunity Number: PAR-16-290 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: HealthCFDA Number: 93.352Eligible Applicants Public and State controlled institutions of higher educationNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationPrivate institutions of higher educationOthers (see text field entitled "Additional Information on Eligibility" for clarification)Agency Name: HHS-NIH11Closing Date: ...
Source: Grants.gov - May 26, 2016 Category: Research Tags: Health Source Type: funding
HIV/AIDS Vaccine Facility (C06)
Funding Opportunity PAR-16-290 from the NIH Guide for Grants and Contracts. Development and testing of AIDS vaccines are high priorities for NIH-supported research (NOT-OD-15-137). This Funding Opportunity Announcement (FOA) invites applications from qualified academic institutions to apply for support to upgrade existing functioning space to Current Good Manufacturing Practice (CGMP) standards for production of next generation candidates for HIV/AIDS vaccines, with the goal of creating sufficient quantities of immunogens to conduct Phase I clinical trials. The applicants should: a) demonstrate the highest level of e...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 25, 2016 Category: Research Source Type: funding
Blm-wo, wild horse fertility vaccine adjuvant efficacy research
Funding Opportunity Number: L16AS00097 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: Natural ResourcesCFDA Number: 15.229Eligible Applicants Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"Agency Name: DOI-BLMClosing Date: Jun 24, 2016Award Ceiling: $80,000Expected Number of Awards: 1Creation Date: Apr 24, 2016Funding Opportunity Description: BACKGROUND: Wild Horse and Burro populations on BLM lands exceed allowable mana...
Source: Grants.gov - April 25, 2016 Category: Research Tags: Natural Resources Source Type: funding
Consideration of Relevant Biological Variables in NIH Grant Applications
In part three of our series on rigor and transparency in research grant and career development award applications, we focus on consideration of relevant biological variables.
Updated instructions for the Approach section of the Research Strategy ask the applicant to:
Explain how relevant biological variables, such as sex, are factored into research designs and analyses for studies in vertebrate animals and humans. For example, strong justification from the scientific literature, preliminary data, or other relevant considerations, must be provided for applications proposing to study only one sex.
Several blog posts have bee...
Source: NIH Extramural Nexus - January 29, 2016 Category: Research Authors: Mike Lauer Tags: blog Open Mike applications biological variables reproducibility Resources rigor SABV Source Type: funding
